60 Degrees Pharmaceuticals Announces First Quarter 2024 Results marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease..
Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine’s presumed mode of action against C. auris is differentiated from standard of care treatmentMonash University will conduct the studies beginning in second quarter of 2024 WASHINGTON, Feb. 20, 2024 (GLOBE NEWSWIRE) 60 Degrees Pharmaceuticals, Inc. (the “Company,” “60P” or “60 Degrees Pharmaceuticals”) (NASDAQ: SXTP; SXTPW), specialists in developing and marketing medicines for infectiou
To lead U.S. commercial relaunch of ARAKODA® for malaria preventionWill support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis WASHINGTON,.
WASHINGTON, Jan. 16, 2024 60 Degrees Pharmaceuticals, Inc. , a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it.